Polyethylene glycol modified interferon therapy

• US 5,908,621 A
• Filed: 04/29/1997
• Issued: 06/01/1999
• Est. Priority Date: 11/02/1995
• Status: Expired due to Term

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Affrime, Melton B., Glue, Paul, Cutler, David L.
• Primary Examiner(s): Scheiner, Toni R.
• Application Number:
  US08/839,101
• Time in Patent Office: 763 Days
• Field of Search: 424/85.4, 424/85.7
• US Class Current: 424/85.7
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals

Abstract

A method comprising administering a PEG₁₂₀₀₀ -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.

Claims

1. A method of treating hepatitis C viral infections in mammals which comprises administering PEG₁₂₀₀₀ -interferon alpha-2b in an amount of 0.5-2.0 μ

g/kg in one or two doses per week to mammals in need of such treating.

2. A method of treating hepatitis C viral infections in mammals which comprises administering PEG₁₂₀₀₀ -interferon alpha-2b in an amount of 0.5 μ

g/kg twice per week to mammals in need of such treating.

3. A method of treating hepatitis C viral infections in mammals which comprises administering PEG₁₂₀₀₀ -interferon alpha-2b in an amount of 2.0 μ

g/kg once per week to mammals in need of such treating.

4. A method of treating hepatitis C viral infections in mammals which comprises administering PEG₁₂₀₀₀ -interferon alpha-2b in an amount of 0.5, 1.0 or 1.5 μ

g/kg once per week to mammals in need of such treating.